Press Releases

Media Inquiries - media@caredx.com

Date	Title and Summary	Additional Formats
Toggle Summary May 24, 2022	CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation CareDx Expands Transplant Portfolio in Europe SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for	View HTML
Toggle Summary May 18, 2022	CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically	View HTML
Toggle Summary May 17, 2022	In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 of 2 Patents Originally Asserted Against CareDx Natera Recycles Old IP for New Lawsuits SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant	View HTML
Toggle Summary May 11, 2022	CareDx Showcases Latest Innovation in Transplantation at European EFI 2022 Conference Posters and Symposium Feature Latest Advances in AlloSeq Portfolio Including HLA Typing and Hematopoietic Stem Cell and Organ Transplant Monitoring SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery,	View HTML
Toggle Summary May 05, 2022	CareDx Reports First Quarter 2022 Results SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today reported	View HTML
Toggle Summary May 05, 2022	CareDx Validates Clinical Performance of AlloMap Kidney to Comprehensively Assess Transplant Rejection OKRA Multi-Center Prospective Study Confirms AlloMap Kidney Detects ABMR and TCMR Allograft Rejection SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically	View HTML
Toggle Summary Apr 28, 2022	CareDx Congratulates Board Member Dr. Hannah Valantine on ISHLT Lifetime Achievement Award SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced	View HTML
Toggle Summary Apr 28, 2022	CareDx Extends Artificial Intelligence Leadership to Heart Transplantation New Addition to CareDx HeartCare Multimodality Portfolio Can Enable More Precise, Personalized Patient Care SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of	View HTML
Toggle Summary Apr 27, 2022	CareDx to Report First Quarter 2022 Financial Results SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report	View HTML
Toggle Summary Apr 27, 2022	International Society for Heart and Lung Transplantation Foundation Selects Reg Seeto as Corporate Chair CareDx CEO and President, Reg Seeto, Joins ISHLT Foundation Global Steering Committee Focused on Driving Innovations for Heart and Lung Transplant Patients SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery,	View HTML